Rolling BLA submission for nomlabofusp is underway, supported by positive long-term open-label data showing sustained frataxin increases and clinical improvements in Friedreich's ataxia. Safety profile is manageable, with anaphylaxis risk primarily in previously exposed patients. Phase III trial to begin in Q3, targeting a broad patient population.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.